Reduced Dexamethasone Pre-Medication Dose in Elderly Patients Receiving Weekly Docetaxel

Stopped early · Phase 2

Conditions studied: Breast Cancer, Lung Cancer

In brief

This study is to explore the feasibility of an alternative dose of dexamethasone pre-medication in older breast and lung cancer patients who are receiving weekly docetaxel chemotherapy.

Key facts

Study ID

NCT00215748

Run by

Geriatric Oncology Consortium

People needed

40

Starts

2004-08-01

Expected to finish

2007-04-01

Last updated by the study team

2007-11-16

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• age ≥ 65 years;
• breast or lung cancer patients to receive docetaxel therapy as per protocol;
• corticosteroid administration, other than what is prescribed in this protocol, is not permitted during study participation, except topical administration and for adverse events;
• performance status ECOG 0-2;
• peripheral neuropathy ≤ 1;
• adequate kidney and liver functions
• signed study-specific informed consent

You may not qualify if…

• Patients who have received an investigational drug within 4 weeks of registration;
• Prior or concurrent malignancies (other than surgically treated carcinoma in situ;
• Serious medical or psychiatric illness which would prevent informed consent;
• Life expectancy < 3 months;
• Active uncontrolled bacterial, viral, or fungal infection until these conditions are corrected or controlled.

Where it is running

• Study site — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.